bluuebunny/crossref_metadata_2025_split huggingface dataset:
CLASSIFICATION OF THE FOSSORIAL, PREDACEOUS AND PARASITIC WASPS, OR THE SUPERFAMILY VESPOIDEA
Authors: Ashmead William. H. 
Published: February 2010

1894. Myrmosini, Tribe II. (partim), Fox; Proc. Acad, Sci., Phila., p. 273.1896. Myrmosini, Tribe II. (partim), Ashmead; Trans. Am. Ent. Soc., XXII., p. 179,180.1899. Methocinæ, Tribu 3e (partim) André; Spec. Hym. d'Eurr Tom. 8,p. 58 and 71.1903. Methocinæ, subfamille (partim). André; Wytsman's Gen. Ins. Fam. Mutillidæ, p.6.Mr. Ernest André's conception of this subfamily is erroneousl he has placed in it a number of genera that do not belong to the family Thynnidæat all, but are genuine Myrmosids, and represent my tribe Chyphotini. Moreover André has incorrectly classifed all of these genera in the family Mutillidæ an error Fox and myself also fell into years ago, before we had studied the Thynnidæ.
NOTES ON CULEX KELLOGGII, THEOBALD
Authors: Coquillett D. W. 
Published: February 2010

In the Canadian Entomologist for August, Mr. Theobald described a Cullex Kelloggii as new; the description agrees well with the specimens on which I founded Culex tarsalis*, and undoubtely refers to the same species.My specimens were from the same lot as the one which Dr. Williston described as Culex, n. sp. †, to which description Lieut. Giles applied the name of Culex Willistoni, n. sp.‡ the latter name is therefore also synonym of tarsalis.
EUCORETHRA, A GENUS OF CULICIDÆ
Authors: Coquillett D. W. 
Published: February 2010

Eucorethra, Underwood*Intermediate between Corethrella and Sayomyia, having the antennæ 14-jointed, as in the former, but the spaces between the verticels almost bare, as in the latter; differing from each in the much shorter second joint of the antennæ, which is only slightly longer than wide. Antennæ of male rather robust, submoniliform on the basal half, the first six joints only slightly longer than wide, the remaining joints increasing in length and decreasing in diameter toward the apex, the antepenult about half as long as the penult, verticels composed on numerous very long bristly hairs except on the last joint; antennæ of female nearly cylindrical, the joints gradually increasing in length to the apex, scarcely thickened at the insertion of the verticels, which consist of a few rather short bristly hairs; probosics about one and one-half times as long as height of head, palpi inserted near three-fourths of its length, 4-jointed; first tarsal joint much longer than the second; venation as in Culex.
LIST OF CANADIAN COLEOPTERA
Authors: Evans John. D. 
Published: February 2010

Gyrinidœ1505, Gyrinus minutus, Fab., '80.*1514 Gyrinus aquiris, Lec., '80.Gyrinus sp., ' 80.Hydrophilidœ1542, Helophorus oblongus, Lec, '79, '80.1543, Helophorus lacustris, Lec., '80.1546, Helophorus linearis, Lec., '80.1597, Hydrocharis obtusatus, Say, '80.1614, Berosus striatus, Say, '80, '81.*1622, Laccobius ellipticus, Lec., '80.1653, Hydrobius fuscipes, Linn., '79, '81.Cercyon, sp., '81.
SOME NOTES ON APHIDIDÆ
Authors: Cockerell T. D. A. 
Published: February 2010

Macrosiphum ambrosiœ (Thomas).— Siphonophora ambrosiœ, Thomas, Bull. Ill. State Lab. Nat. Hist., 1878, p.4.Found at Pecos, New Mexico, on Lactuca. The following account is based on the Pecos specimens:Very dark brown, very shiny; legs, antennæ and nectaries black, except that the basal part of legs, to near middle of femora, is brownishwhite; stigma pale green; cauda of winged ♀ yellowish-white.
A NEW GENUS AND SOME NEW SPECIES OF HYMENOPTERA FROM THE PHILIPPINE ISLANDS
Authors: Ashmead William. H. 
Published: February 2010

All of the Hymenoptera described in this paper were received from Father W. A. Stanton, Who captured them in the Observatory Garden at Manila, P. I.Family X.—Stelididæ Cœlioxys, Latr.œiCœlioxys Manilœ, new species.—♀. Length 6.5mm. Black; the cheeks, temples, clypeus and the fae upwards to the front ocellus, the mesopleura, sternum, coxæ, metathorax, and the apical margins of the ventral and dorsal abdominal segments, clothed, rather densely, with a whitish pubescence, sometimes tinged with yellow; there are also triangular spots of a yellowish pubescence on the anterior and posterior margins of the mesonotum and on the base of the scutellum; the head and thorax are rather coarsely, closely punctured, opaque, while the abdomen is shining, although distinctly punctate, the puncutures sparse and separated; the pygidium is bi-impressed at apex with a short median carina separating the impressions, the punctures being coarser and closer in the impressions or towards apex; the mandibles medially and the legs are red, the femora beneath and the tibiæ outwardly being clothed with a short, fine, dense, whitish pubescence.
A NEW SPECIES OF XYLINA
Authors: Engel Henry 
Published: February 2010

Xlina nigrescens. sp. nov.— Two males and one female.Upper part of head and thorax stone-gray, front of head light brown, surmounted by a well-defined umber brown line beneath base of antennæ. This line is continuous along lower margin of patagiæ and ver contrasting from the gray thorax. The thorax is rather short and square. Thoracic vestiture intermixed with flattenedhair. Thoracic crest slightly raised and defined by a patch of dark brown hair. Collar with a faint line near tip, not contrasting. Palpi are reddish-gray, strongly marked laterally with an umber-brown line outwardly.
NEW SPECIES OF NORTH AMERICAN LEPIDOPTERA
Authors: Barnes William 
Published: February 2010

Stiria aliaga, n. sp.—♂. Expanse, 30 mm.Ground colour even chrome-yellow, a shade lighter beyond t.p. line. Small ochraceous spot at inner thrid of cell, one towards its outer end and traces of one beyond. These are about equidistant from each other. T. p. line the only other marking on fore wing. This is quite faint, ochraceous, wavy and cannot be followed to costa in the speciments before me. The fringe is darker than wing, of a somewhat “Ashes of Roses” colour.
MANITOBA MICRO-LEPIDOPTERA
Authors: Kearfott W. D. 
Published: February 2010

Diastictis argyralis, Hbn.— Beulah, IX, 14.Nomophila noctuella, Schiff.—Cartwright.Loxostege chortalis, Grt.— Aweme, VI, 6, to VI, 19; Souris.Diasemia plumbosignalis, Fern.— Aweme, VII, 1; Souris; Wattsview.
A FIRST LIST OF ONTARIO ODONATA
Authors: Walker E. M. 
Published: February 2010

The following list of Odonata is mainly the result of four seasons collecting in various parts of Ontario, but chiefly in three localities, viz: Toronto, De Grassi Point, Lake Simcoe, and Algonquin Park.Although most of the material was collected by the writer, the list has been considerably lengthened by the records of captures made by other collectors. Among these should be mentioned the collections of Dr. Wm. Brodie, in the Educational Dept., Toronto; many specimens taken in Algonquin Park by Prof. Macoun in 1900, and by Mr. Paul Hahn in 1903–4; a considerable number from the collection of the Biological Dept. of the University of Toronto, consisting chiefly of alcholic specimens of nymphs and imagoes taken at the Biological Experiment Station at Go Home, Georgian Baym and a few collected and presented to the Department by the late Mr. R. T. Anderson; and finally, a small collection from Thessalon, Algoma, belonging to Miss Rounthwaite, of Toronto.
DESCRIPTIONS OF TWO NEW GEOMETRID MOTHS FROM ALBERTA
Authors: Taylor Geo. W. 
Published: February 2010

Palpi and front dark gray, with a plentiful intermixture of brown scales. Thorax dark fuscous. Abdomen above dark gray, beneath lighter gray.Fore wing: ground colour gray, but almost entirely obscured by blackish-brown scales.The basal area is darkened by about four parallel wavy fuscous lines; the space between the basal and intradiscal lines is paler and crossed by two dark lines parallel with the basal.
Distinct Phenotype and Function of NK Cells in the Pancreas of Nonobese Diabetic Mice
Authors: Brauner Hanna , Elemans Marjet , Lemos Sara , Broberger Christian , Holmberg Dan , Flodström-Tullberg Malin , Kärre Klas , Höglund Petter 
Published: February 2010

Abstract
Little is known about target organ-infiltrating NK cells in type 1 diabetes and other autoimmune diseases. In this study, we identified NK cells with a unique phenotype in the pancreas of NOD mice. Pancreatic NK cells, localized to the endocrine and exocrine parts, were present before T cells during disease development and did not require T cells for their infiltration. Furthermore, NK cells, or NK cell precursors, from the spleen could traffic to the pancreas, where they displayed the pancreatic phenotype. Pancreatic NK cells from other mouse strains shared phenotypic characteristics with pancreatic NK cells from NOD mice, but displayed less surface killer cell lectin-like receptor G1, a marker for mature NK cells that have undergone proliferation, and also did not proliferate to the same extent. A subset of NOD mouse pancreatic NK cells produced IFN-γ spontaneously, suggesting ongoing effector responses. However, most NOD mouse pancreatic NK cells were hyporesponsive compared with spleen NK cells, as reflected by diminished cytokine secretion and a lower capacity to degranulate. Interestingly, such hyporesponsiveness was not seen in pancreatic NK cells from the nonautoimmune strain C57BL/6, suggesting that this feature is not a general property of pancreatic NK cells. Based on our data, we propose that NK cells are sentinel cells in a normal pancreas. We further speculate that during inflammation, pancreatic NK cells initially mediate proinflammatory effector functions, potentially contributing to organ-specific autoimmunity, but later become hyporesponsive because of exhaustion or regulation.
Impact of the medicare modernization act of 2003 on utilization and spending for medicare part B–covered biologics in rheumatoid arthritis
Authors: Doshi Jalpa A. , Li Pengxiang , Puig Andrea 
Published: January 2010

AbstractObjectiveTo examine changes in utilization and expenditures for infliximab in rheumatoid arthritis (RA) patients associated with the 2 changes implemented by the Medicare Prescription Drug Improvement and Modernization Act (MMA) of 2003, specifically 1) reductions in physician reimbursement for Part B drugs between 2003 and 2005 and 2) availability of alternative RA biologics in 2006.MethodsUsing 2002–2006 5% Medicare files, nationally representative estimates of infliximab use and expenditures were estimated in annual cross‐sectional samples of RA beneficiaries. Infliximab initiation and continuation rates were estimated in 2‐year longitudinal cohorts (2005–2006 versus 2002–2003, 2003–2004, and 2004–2005).ResultsTotal payments (in 2006 dollars) for infliximab increased from $357 million in 2002 to $492 million in 2006. The largest annual increase in infliximab payments occurred in the pre‐MMA period from 2002 to 2003, wherein payments per RA patient increased by 31%. From 2003 to 2004, despite the reduction in payments brought by the MMA, there was a 4% increase in total expenditures for infliximab per RA patient driven by an increase in utilization factors. Total payments for infliximab per RA patient actually decreased from 2004 to 2005, when reimbursement was further reduced. Continuation and initiation rates for infliximab use remained unchanged in 2006, as compared with previous years.ConclusionInfliximab expenditures increased from 2002 to 2006, yet the passage of the MMA was associated with a remarkable slowdown in the rate of increase in expenditures. There was no evidence of significant substitution of infliximab with other biologics made available in 2006.
Pregnancy outcomes in women with Familial Mediterranean Fever receiving colchicine: Is amniocentesis justified?
Authors: Ben‐Chetrit Eli , Ben‐Chetrit Avraham , Berkun Yackov , Ben‐Chetrit Eldad 
Published: January 2010

AbstractObjectiveTo evaluate the outcome of pregnancies in women with familial Mediterranean fever (FMF) who are taking colchicine, and to reconsider the justification for amniocentesis in these women.MethodsThe outcome of 179 pregnancies in a group of women with FMF taking colchicine was compared with the outcome of 197 pregnancies in women with FMF who did not take colchicine during pregnancy and with 312 pregnancies in another cohort of healthy pregnant women of similar age and ethnicity.ResultsThere was no difference in the 3 groups regarding early abortions, late abortions, or congenital malformations. There was a mild trend towards a better outcome for the colchicine‐treated group but these results did not reach statistical significance.ConclusionTreatment with colchicine during pregnancy in patients with FMF is beneficial in controlling the disease while not affecting the outcome of the pregnancy; therefore there is no justification for recommending amniocentesis in women taking colchicine solely because of this treatment.
Incidence of childhood linear scleroderma and systemic sclerosis in the UK and Ireland
Authors: Herrick Ariane L. , Ennis Holly , Bhushan Monica , Silman Alan J. , Baildam Eileen M. 
Published: January 2010

AbstractObjectiveChildhood scleroderma encompasses a rare, poorly understood spectrum of conditions. Our aim was to ascertain the incidence of childhood scleroderma in its different forms in the UK and Ireland, and to describe the age, sex, and ethnicity of the cases.MethodsThe members of 5 specialist medical associations including pediatricians, dermatologists, and rheumatologists were asked to report all cases of abnormal skin thickening suspected to be localized (including linear) scleroderma or systemic sclerosis (SSc) in children <16 years of age first seen between July 2005 and July 2007.ResultsWe received notification of 185 potential cases, and 94 valid cases were confirmed: 87 (93%) with localized scleroderma and 7 (7%) with SSc. This gave an incidence rate per million children per year of 3.4 (95% confidence interval [95% CI] 2.7–4.1) for localized scleroderma, including an incidence rate of 2.5 (95% CI 1.8–3.1) for linear scleroderma, and 0.27 (95% CI 0.1–0.5) for SSc. Of the 87 localized cases, 62 (71%) had linear disease. Of localized disease cases, 55 (63%) were female, 71 (82%) were classified as white British, and the patients' mean age when first seen in secondary care was 10.4 years. Of the 7 SSc cases, all were female, 6 (86%) were white British, and the mean age when first seen was 12.1 years. The median delay between onset and being first seen was 13.1 months for localized scleroderma and 7.2 months for SSc.ConclusionThese data provide additional estimates of the incidence of this rare disorder and its subforms.
Impact of systemic lupus erythematosus on health, family, and work: The patient perspective
Authors: Robinson Don , Aguilar Daniel , Schoenwetter Melissa , Dubois Robert , Russak Simcha , Ramsey‐Goldman Rosalind , Navarra Sandra , Hsu Benjamin , Revicki Dennis , Cella David , Rapaport Mark Hyman , Renahan Kevin , Ress Richard , Wallace Daniel , Weisman Michael 
Published: January 2010

AbstractObjectiveQualitative research among patients with systemic lupus erythematosus (SLE) can identify aspects of the disease relevant to clinical research and practice. A phenomenological, mixed‐method approach was used to investigate these disease‐driven health issues.MethodsA convenience sample of patients with SLE from Los Angeles County, California was recruited from a private, community‐based rheumatology practice for participation in focus groups and interviews. Semistructured discussions explored disease manifestations and impact. A self‐administered questionnaire evaluated the occurrence and importance of disease issues previously identified from literature. Patient health issues were identified through convergence using 1) qualitative analysis of focus group transcripts and 2) quantitative analysis of the questionnaire. Patients were also asked about their ability to accurately recall disease experiences.ResultsFocus group participants (n = 23) had a mean age of 43 years and a mean disease duration of 8 years; 19 (83%) were women and 14 (61%) were white. The most frequent health issues identified by focus group transcript analysis were pain (83%), fatigue (61%), work or school impairment (48%), skin manifestations (43%), and skin sensitivity (43%). Questionnaire findings were similar: the most frequent health issues were inability to do previous activities (87%), fatigue (87%), pain (87%), and work or school impairment (83%). Most interviewed patients (7 of 10) reported an ability to accurately recall disease issues between 24 hours and 7 days.ConclusionSLE patients reported signs and symptoms that could significantly impact their functioning in daily life. Treatments that substantially improve these disease manifestations would offer considerable benefit to patients, treating physicians, and general society.
Responsiveness of self‐report and therapist‐rated upper extremity structural impairment and functional outcome measures in early rheumatoid arthritis
Authors: Adams Jo , Mullee Mark , Burridge Jane , Hammond Alison , Cooper Cyrus 
Published: January 2010

AbstractObjectiveTo provide a responsiveness analysis of the self‐report and therapist‐rated upper extremity functional outcome measures used in a rehabilitation trial.MethodsA variety of commonly used therapist‐assessed and self‐report structural impairment and functional outcome measures were compared for the ability to detect and measure change in wrist and hand status in an early rheumatoid arthritis population over 12 months. Responsiveness was measured using the standardized response mean (SRM) and effect size (ES).ResultsThe most responsive measures were the Michigan Hand Outcomes Questionnaire (SRM 0.49 [95% confidence interval (95% CI) 0.27, 0.72], ES = 0.37 [95% CI 0.21, 0.54]), dominant metacarpophalangeal joint ulnar deviation (SRM 0.46 [95% CI 0.27, 0.65], ES = 0.58 [95% CI 0.34, 0.82]), and mean power handgrip test (SRM 0.45 [95% CI 0.26, 0.64], ES = 0.32 [95% CI 0.18, 0.45]) The least responsive measure was the Health Assessment Questionnaire (SRM −0.12 [95% CI −0.31, 0.08], ES = −0.08 [95% CI −0.21, 0.05]).ConclusionOver 12 months, there was substantial variation in wrist and hand outcome measures to detect change over time in an early RA population. Careful consideration is required to choose the most appropriate measure that can detect change.
Increased levels of serum pentraxin 3, a novel cardiovascular biomarker, in patients with inflammatory rheumatic disease
Authors: Hollan Ivana , Bottazzi Barbara , Cuccovillo Ivan , Førre Øystein T. , Mikkelsen Knut , Saatvedt Kjell , Almdahl Sven Martin , Mantovani Alberto , Meroni Pier Luigi ,   Feiring Heart Biopsy Study Group
Published: January 2010

AbstractObjectivePentraxin 3 (PTX3), a key component of innate immunity, is a strong marker of disease severity in coronary artery disease (CAD). The aim of this study was to compare levels of serum PTX3 in CAD patients with and without inflammatory rheumatic disease (IRD) and in healthy controls.MethodsWe examined 69 patients with IRD (CAD/IRD group) and 53 patients without IRD (CAD/non‐IRD) referred to coronary artery bypass grafting, and 30 healthy controls.ResultsThe mean ± SD serum PTX3 level in the CAD/IRD group was 1.96 ± 0.98 ng/ml; this was statistically significantly higher than that of the CAD/non‐IRD (1.41 ± 0.74 ng/ml) and healthy control (1.21 ± 0.59 ng/ml) groups. In contrast to most other IRDs, serum PTX3 levels were relatively low in patients with systemic lupus erythematosus (SLE) and other systemic connective tissue diseases. In sex‐ and age‐adjusted analysis, IRD, acute coronary syndromes, and low alcohol intake were associated with higher serum PTX3 levels.ConclusionCAD patients with IRD had higher mean serum PTX3 levels than patients without IRD and healthy controls. In addition, acute coronary syndromes and low alcohol intake independently predicted higher serum PTX3 levels. Higher serum PTX3 levels in IRD may be related to the higher cardiovascular risk of IRD patients. Circulating PTX3 could likely be used as a biomarker for severity of cardiovascular disease in IRDs; its importance, however, might be limited in SLE and related disorders.
Separate influences of birth order and gravidity/parity on the development of systemic sclerosis
Authors: Cockrill Tonya , del Junco Deborah J. , Arnett Frank C. , Assassi Shervin , Tan Filemon K. , McNearney Terry , Fischbach Michael , Perry Marilyn , Mayes Maureen D. 
Published: January 2010

AbstractObjectiveBirth order has been valuable in revealing the role of environmental influences on the risk of developing certain diseases such as allergy and atopy. In addition, pregnancy has profound effects on the immune system such as short‐term effects that permit fetal survival as well as longer‐term effects that could influence late‐onset diseases. In order to better evaluate these influences, we studied the association of birth order and gravidity/parity as risk factors for systemic sclerosis (SSc; scleroderma).MethodsData regarding SSc cases and their unaffected sibling controls were obtained from the Scleroderma Family Registry and DNA Repository. The case‐sibling design was used to minimize confounding due to differences in age, race, ethnicity, or calendar time. The gravidity/parity analysis was based on sibships with at least one SSc‐affected and one unaffected sister.ResultsBirth order was examined in 974 sibships, comparing SSc cases (n = 987) with their unaffected siblings (n = 3,088). The risk of scleroderma increased with increasing birth order (odds ratio [OR] 1.25, 95% confidence interval [95% CI] 1.06–1.50 for birth order 2–5; OR 2.22, 95% CI 1.57–3.15 for birth order 6–9; and OR 3.53, 95% CI 1.68–7.45 for birth order 10–15). Gravidity/parity was analyzed in 168 sibships (256 unaffected sisters, 172 SSc cases). We found an association between a history of one or more pregnancies and SSc (OR 2.8).ConclusionBirth order and pregnancy were independently associated with a higher risk of developing SSc. These findings suggest that immune development in early childhood and/or pregnancy‐associated events, including but not limited to microchimerism, plays a role in SSc susceptibility.
Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome
Authors: Ruffatti A. , Calligaro A. , Hoxha A. , Trevisanuto D. , Ruffatti A. T. , Gervasi M. T. , Cuffaro S. , Pengo V. , Punzi L. 
Published: January 2010

AbstractObjectiveTo evaluate the relationship between the antiphospholipid profile and clinical characteristics of pregnant women with antiphospholipid syndrome (APS) and neonatal outcome.MethodsWe retrospectively considered 109 treated pregnancies of 93 patients with primary APS and reviewed the medical records of their 111 infants. Neonatal outcome was assessed using the following variables: weeks of gestational age at delivery, percentiles of birth weight, Apgar score at 5 minutes, need for cardiopulmonary resuscitation in the delivery room, time in the neonatal intensive care unit, infections, and other neonatal complications. Univariate statistical analysis was performed to evaluate the relationship between APS maternal features and neonatal outcome parameters.ResultsWhen maternal APS features and variables of infant outcome were analyzed, it was evident that lupus anticoagulant (LAC), triple antiphospholipid positivity, and history of vascular thrombosis were significantly associated with some parameters of a poor infant outcome. History of pregnancy morbidity alone was, instead, significantly correlated to the variables of favorable neonatal outcome.ConclusionThere seems to be more than one kind of pregnant woman with APS. Even when treated with a second‐line therapy plan, mothers with LAC and/or triple antiphospholipid positivity and/or previous thromboembolism seem to have a high probability of poor neonatal outcome, whereas those with pregnancy morbidity alone, treated with conventional drugs, seem to have a high probability of favorable outcome.